Aura Biosciences, Inc. AURA Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aura Biosciences, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aura Biosciences, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Aura Biosciences, Inc. (AURA) reported unrealized gains (losses) on available-for-sale securities of -$78K in Q1 2026.
- How has Aura Biosciences, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Aura Biosciences, Inc.'s unrealized gains (losses) on available-for-sale securities increased by 43.1% year-over-year, from -$137K to -$78K.
- What is the long-term trend for Aura Biosciences, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2023 to 2025), Aura Biosciences, Inc.'s unrealized gains (losses) on available-for-sale securities has grown at a -45.9% compound annual growth rate (CAGR), from $611K to -$179K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- The change in the fair value of available-for-sale investment securities that has not yet been realized through a sale. This metric captures market-driven fluctuations in the value of the company's investment portfolio that are excluded from net income. It provides insight into the volatility and unrealized performance of the company's treasury investment strategy.